Natco Pharma gets USFDA EIR for Visakhapatnam plant
In short
Natco Pharma has received the USFDA’s Establishment Inspection Report for its Visakhapatnam plant. The plant had an August inspection that led to four Form-483 observations and a Voluntary Action Indicated classification.
What the reporting says
Natco Pharma received the USFDA’s Establishment Inspection Report for its Visakhapatnam plant after an August inspection, according to BusinessLine. The inspection drew four Form-483 observations, and the regulator classified the site as Voluntary Action Indicated. The development suggests the plant has cleared the inspection process, though the source only states the regulator’s classification and observations.
Why it matters
Natco Pharma received the USFDA’s Establishment Inspection Report for its Visakhapatnam plant after an August inspection, BusinessLine reported. The inspection resulted in four Form-483 observations, and the regulator classified the facility as Voluntary Action Indicated. This is relevant to Natco Pharma because the USFDA status affects how the plant is viewed on compliance and manufacturing oversight.